Nutriband Inc. Warrant (NTRBW NASDAQ) stock market data APIs
$1.9651
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
Nutriband Inc. Warrant Financial Data Overview
Price chart is built with
Anychart
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Prev. Close
1.9651
Open
1.9651
High
1.9651
Low
1.9651
52 wk Range
0.75-5.25
Market Cap
0
Revenue
2 578 K
EPS
-0.0818
Beta
1.287
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nutriband Inc. Warrant data using free add-ons & libraries
Get Nutriband Inc. Warrant Fundamental Data
Nutriband Inc. Warrant Fundamental data includes:
- Net Revenue: 2 578 K
- EBITDA: -6 546 252
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-07-31
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nutriband Inc. Warrant News
New
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cas...
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it ...
Nutriband CEO Steps Down Temporarily; FDA Meeting Granted For AVERSA Fentanyl
(RTTNews) - Nutriband Inc. (NTRB, NTRBW), a pharmaceutical company, on Monday announced that Chief Executive Officer Gareth Sheridan will be stepping down from the role for three months to enter the I...
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
